Table 2. Univariate logistic regression analysis of potential risk factor in predicting CMV reactivation in CMV seropositive kidney transplant recipients.

Univariate Logistic Regression (n = 117)
Variable	n (%)	p	Odds ratio (95% CI)
Older age cohort	63 (53.85)	0.003	1.31 (1.10,1.56)
Sex female	50 (42.74)	0.855	0.98 (0.82,1.18)
DM	42 (35.90)	0.0144	1.26 (1.05, 1.51)
Prior transplant	21 (17.95)	0.0319	0.78 (0.82,0.98)
CMV seropositive donor	86 (73.50)	0.589	1.06 (0.86,1.30)
No induction (=steroids only)	18 (15.38)	0.404	0.90 (0.70,1.15)
Basiliximab induction	61 (52.14)	0.023	1.23 (1.03,1.47)
Rejection	15 (12.8)	0.638	0.94 (0.72, 1.23)
Augmented I/S	14 (11.97)	0.471	0.90 (0.69, 1.20)
BKV	31 (27.19)	0.724	0.96 (0.79, 1.18)
Use of CMV directed ppx for at least 30 days (GCV/VGCV)	59 (50.43)	0.411	1.08(0.90,1.29)
Bacteremia	17 (14.30)	0.99	1.00 (0.77,1.29)
Pneumonia	13 (11.11)	0.43	1.12 (0.84,1.49)
Urinary tract infection	51 (43.59)	0.729	1.03 (0.86, 1.24)
Admission for infection [patient level] ¥	52 (44.44)	0.382	1.08 (0.91, 1.30)
Surgery [patient level] ¥¥	30 (25.64)	0.577	1.06 (0.86, 1.30)
Ambulation before transplant (independent/needs assistance/dependent) ¥¥¥	99 (84.62)	0.365	0.92 (0.78, 1.10)

^¥52 patients with at least one admission for infection.

^¥¥30 patients with at least 1 re-operation/surgery (39 total episodes).

^¥¥¥Missing in 2 cases. DM: diabetes mellitus; I/S: immunosuppression; BKV: BK polyomavirus; ppx: prophylaxis; GCV: ganciclovir; VGCV: valganciclovir.